Moderna is set to receive $590m in funding from the US Department of Health and Human Services (HHS) to expedite the ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

is an mRNA-based vaccine that sends signals to your cells to produce the same protein F that causes the immune reaction that fights against RSV. These vaccines are recommended and available for ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

RSV Vaccines Effective ... VISION Network researchers report that across the board these ... New mRNA Vaccine Created to Prevent and Treat C. Difficile Oct. 17, 2024 — A new vaccine provides ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024 ... This figure includes a mere $10 million in sales of the new RSV vaccine following its third-quarter launch, underscoring the ...

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...